DMRA vs PCRX: stock comparison and AI forecast
Damora Therapeutics, Inc. (DMRA) and Pacira Biosciences, Inc. (PCRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DMRA Damora Therapeutics, Inc.
- Market Cap
- $1.46B
- P/E Ratio
- 2.3x
- Size
- small-cap
- AI Forecast
PCRX Pacira Biosciences, Inc.
- Market Cap
- $1.45B
- P/E Ratio
- 49.2x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- DMRA and PCRX have similar market capitalizations ($1.46B and $1.45B).
- DMRA trades at 2.3 times trailing earnings, PCRX at 49.2 times.
- PCRX carries 0.69 times debt per unit of equity, against 0.07 times for DMRA.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DMRA | PCRX |
|---|---|---|
| Market Cap | $1.46B | $1.45B |
| P/E Ratio | 2.27x | 49.23x |
| P/B Ratio | 2.95x | 2.04x |
| EPS | $10.46 | $0.74 |
| Book Value/Share | $8.03 | $17.87 |
| Revenue/Share | – | $18.65 |
| FCF/Share | – | $4.24 |
Profitability & Margins
| Metric | DMRA | PCRX |
|---|---|---|
| ROE | – | 5.3% |
| ROA | – | 3.1% |
| ROIC | -61.3% | 3.3% |
| Gross Margin | – | 78.7% |
| Operating Margin | – | 4.8% |
| Net Margin | – | 5.1% |
| EBT Margin | – | 5.0% |
| Tax Rate | -0.1% | -2.1% |
Financial Health
| Metric | DMRA | PCRX |
|---|---|---|
| Current Ratio | 14.80x | 4.68x |
| Quick Ratio | – | 3.65x |
| D/E Ratio | 0.07x | 0.69x |
| Financial Leverage | 1.07x | 1.69x |
| Interest Coverage | -8.9x | 7.7x |
| Working Capital | $495M | $464M |
Cash Flow
| Metric | DMRA | PCRX |
|---|---|---|
| Operating Cash Flow | -$59M | $177M |
| Free Cash Flow | – | $169M |
| Capital Spending | – | -$8M |
| OCF Growth YoY | – | 25.1% |
| FCF Growth YoY | – | 36.1% |
| FCF/Sales | – | 22.7% |
| CapEx/Sales | – | 1.1% |
Operational Efficiency
| Metric | DMRA | PCRX |
|---|---|---|
| Asset Turnover | – | 0.62x |
| Receivables Turnover | – | 6.0x |
| Inventory Turnover | – | 1.2x |
| Fixed Assets Turnover | – | 5.8x |
| Days Sales Outstanding | – | 60 days |
| Days Inventory | – | 299 days |
| Payables Period | – | 40 days |
| Cash Conversion Cycle | – | 319 days |
Income Statement
| Metric | DMRA | PCRX |
|---|---|---|
| Total Revenue | – | $743M |
| Operating Income | -$304M | $36M |
| Net Income | – | $38M |
| R&D Expense | $98M | $123M |
| SG&A Expense | – | $371M |
| Cost of Goods Sold | – | $158M |
Dividend & Shareholder Information
| Metric | DMRA | PCRX |
|---|---|---|
| Shares Outstanding | 62M | 40M |
| Net Income Growth | – | 75.5% |
| EPS Growth | – | -31.5% |
DMRA vs PCRX: stock comparison and AI forecast
Which is bigger, DMRA or PCRX?
DMRA and PCRX have similar market capitalizations ($1.46B and $1.45B).
Which is cheaper on earnings, DMRA or PCRX?
DMRA trades at 2.3 times trailing earnings, PCRX at 49.2 times.
Which one does Intratio's AI model rank higher, DMRA or PCRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.